CytoDel is a biotechnology company that possesses a proprietary platform for bioengineering recombinant Botulinum neurotoxin ("BoNT"). BoNT is a commercially valuable protein for use in neurological, musculoskeletal and aesthetic medicine, and for the very specific targeting of therapeutic agents to the inside of neurons. CytoDel's platform allows the modulation of BoNT pharmacological activity for applications in aesthetic medicine and neurological disorders. Additionally, CytoDel is harnessing BoNT's ability to target neurons and using their atoxic derivatives as a "Trojan horse" to deliver antidotes into the INSIDE of neurons. One cadidate under development, Cyto-012 vastly improves on existing BoNT based pharmaceuticals by greatly reducing the risk of negative effects. The candidate has applications treating Cerebral Palsy, MS, and Parkinson's disease, CytoDel's second candidate Cyto-111 is being investigated as a tool for delivering biotoxin antidotes directly inside of neurons. The candidate has initial applications in bio-defense.
